DYNAMICS IN CONSUMPTION AND ABC ANALYSIS OF ORAL HYPOGLYCEMIC DRUGS IN AKTOBE, KAZAKHSTAN

Received: 06.02.2025 Accepted: 13.02.2025 Published online: 27.02.2025
DOI: 10.53511/pharmkaz.2025.84.96.015
УДК: 615.254:616.379-008.64
I.B. Kaibagarova¹, A.Z. Mussina¹, G.A. Smagulova¹, N.M. Mavlyudova¹, Zh.Zh. Nurgaliyeva¹, L.M. Zhamaliyeva2
¹ West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
2Department of General Medical Practice No. 2, West Kazakhstan Marat Ospanov Medical University
DYNAMICS IN CONSUMPTION AND ABC ANALYSIS OF ORAL HYPOGLYCEMIC DRUGS IN AKTOBE, KAZAKHSTAN
(2019–2023)
Introduction: Type 2 diabetes mellitus (T2DM) is one of the most common chronic diseases, leading to increased healthcare
costs. In recent years, there has been a shift in prescribing preferences from traditional drugs to innovative medications. This
study aims to analyze trends in prescribing and expenditures on oral hypoglycemic drugs (OHD) in two major outpatient clinics
Objective: To analyze the dynamics of prescribing and expenditures on oral hypoglycemic drugs (OHD) within primary
healthcare in Aktobe, Kazakhstan, over the period 2019–2023.
Materials and Methods: A retrospective analysis was conducted using data from the “Drug Provision” information system of
the Ministry of Health of the Republic of Kazakhstan. The study covered two outpatient clinics. ABC/VEN analysis was applied
to assess the expenditure structure and identify key trends.
Results: Metformin remains the leading first-line drug, although its share in expenditures has declined (to 13.97% in 2023),
while the number of prescriptions has increased. Glimepiride, gliclazide have also decreased, yielding to modern drugs. The
most significant growth was observed for empagliflozin (40.92% in 2023), dapagliflozin, and linagliptin. Differences in
consumption dynamics were identified between the two clinics.
Conclusions: The study highlights the need for regular monitoring of OHD use and rational resource allocation. The findings
can be used to optimize treatment strategies in the context of a limited healthcare budget.
Keywords: type 2 diabetes mellitus, dynamics of use, oral hypoglycemic drugs, pharmacoeconomic analysis, ABC analysis,
primary health care, combination drug therapy, SGLT-2 inhibitors, DPP-4 inhibitors, metformin.

количество просмотров / 👁 14

Leave a Reply

Your email address will not be published. Required fields are marked *